Premium
Double‐Blind Placebo‐Controlled Trial of Quetiapine in Anorexia Nervosa
Author(s) -
Powers Pauline S.,
Klabunde Megan,
Kaye Walter
Publication year - 2012
Publication title -
european eating disorders review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.511
H-Index - 67
eISSN - 1099-0968
pISSN - 1072-4133
DOI - 10.1002/erv.2169
Subject(s) - quetiapine , anorexia nervosa , placebo , psychiatry , eating disorders , psychology , anxiety , anorexia , depression (economics) , quetiapine fumarate , weight gain , medicine , atypical antipsychotic , schizophrenia (object oriented programming) , body weight , antipsychotic , alternative medicine , pathology , economics , macroeconomics
Objective Our objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale–Brown–Cornell Eating Disorder Scale and the Eating Disorder Inventory‐2. Method Participants were randomised to 8 weeks of quetiapine or placebo. Results There are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study. There were no differences between drug and placebo in questionnaire scores, weight or measures of anxiety or depression. Discussion There was no difference between quetiapine and placebo on weight gain or core symptoms. Small effect sizes suggest that a higher number of participants would not increase significant differences between groups. Copyright © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.